Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell 3.3% during mid-day trading on Monday . The company traded as low as $60.47 and last traded at $63.33, with a volume of 2,453,982 shares trading hands. The stock had previously closed at $65.49.

A number of brokerages have recently issued reports on ALNY. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, April 17th. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Thursday, May 5th. Needham & Company LLC reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, May 4th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $117.82.

The company has a 50-day moving average of $61.42 and a 200 day moving average of $63.77. The firm’s market capitalization is $5.66 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.16. The company earned $7.30 million during the quarter, compared to the consensus estimate of $7.79 million. During the same period in the previous year, the business posted ($0.62) EPS. The business’s revenue was down 60.4% compared to the same quarter last year. On average, analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Other hedge funds recently modified their holdings of the company. Sei Investments Co. boosted its stake in shares of Alnylam Pharmaceuticals by 493.7% in the fourth quarter. Sei Investments Co. now owns 19,569 shares of the biopharmaceutical company’s stock worth $1,842,000 after buying an additional 16,273 shares during the last quarter. TD Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 11.5% in the fourth quarter. TD Asset Management Inc. now owns 21,300 shares of the biopharmaceutical company’s stock worth $2,005,000 after buying an additional 2,200 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Alnylam Pharmaceuticals by 9.3% in the fourth quarter. New York State Common Retirement Fund now owns 224,877 shares of the biopharmaceutical company’s stock worth $21,170,000 after buying an additional 19,154 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 9.0% in the fourth quarter. Vanguard Group Inc. now owns 5,048,221 shares of the biopharmaceutical company’s stock worth $475,241,000 after buying an additional 416,709 shares during the last quarter. Finally, Gulf International Bank UK Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock worth $2,175,000 after buying an additional 220 shares during the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.